Abstract
Transcription factor NF-κB regulates the physiological response to a variety of stimuli. The NF-κB pathway has served as a paradigm for analyzing the impact of the covalent protein modifier ubiquitin on signal transduction. The discovery in the early 1990s that degradation of cytosolic NF-κB inhibitors (IκBs) is mediated by the ubiquitin proteasome system (UPS) was the first example for a direct involvement of ubiquitination in cellular signaling. By now it has become clear that the role of the ubiquitin system in the NF-κB pathway extends far beyond triggering IκB destruction. The IκB kinase (IKK) complex is the key regulator of NF-κB. Attachment of ubiquitin chains to the IKK complex and to further upstream components drives NF-κB signaling pathways by promoting the clustering of the signaling network. Whereas ubiquitin conjugation serves a positive function in the NF-κB pathway, ubiquitin deconjugation acts as a negative regulatory feedback mechanism that is critically involved in balancing the strength and the duration of the NF-κB response. Moreover, inactivation of deconjugating enzymes can cause sustained NF-κB activity under pathological conditions like chronic inflammation or cancer. Here we review the impact of the ubiquitin system on the NF-κB signaling network by putting a focus on the enzymes that help to shape the plasticity of the NF-κB response.
Chapter PDF
Similar content being viewed by others
References
Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008; 132:344–62.
Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008; 8:837–48.
Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27:693–733.
Scheidereit C. IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene 2006; 25:6685–705.
Ikeda F, Dikic I. Atypical ubiquitin chains: new molecular signals. ‘Protein Modifications: Beyond the Usual Suspects’ review series. EMBO Rep 2008; 9:536–42.
Komander D, Clague MJ, Urbe S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 2009; 10:550–63.
Jackson PK, Eldridge AG. The SCF ubiquitin ligase: an extended look. Mol Cell 2002; 9:923–5.
Hoffmann A, Natoli G, Ghosh G. Transcriptional regulation via the NF-kappaB signaling module. Oncogene. 2006; 25:6706–16.
Chen ZJ, Parent L, Maniatis T. Site-specific phosphorylation of IkappaBalpha by a novel ubiquitinationdependent protein kinase activity. Cell 1996; 84:853–62.
Bhoj VG, Chen ZJ. Ubiquitylation in innate and adaptive immunity. Nature 2009; 458:430–7.
Tokunaga F, Sakata S, Saeki Y et al. Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat Cell Biol. 2009; 11:123–32.
Lo YC, Lin SC, Rospigliosi CC et al. Structural basis for recognition of diubiquitins by NEMO. Mol Cell 2009; 33:602–15.
Rahighi S, Ikeda F, Kawasaki M et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-kappaB activation. Cell 2009; 136:1098–109.
Yoshikawa A, Sato Y, Yamashita M et al. Crystal structure of the NEMO ubiquitin-binding domain in complex with Lys 63-linked di-ubiquitin. FEBS Lett 2009; 583:3317–22.
Laplantine E, Fontan E, Chiaravalli J et al. NEMO specifically recognizes K63-linked poly-ubiquitin chains through a new bipartite ubiquitin-binding domain. EMBO J 2009; 28:2885–95.
Besse A, Lamothe B, Campos AD et al. TAK1-dependent signaling requires functional interaction with TAB2/TAB3. J Biol Chem 2007; 282:3918–28.
Ishitani T, Takaesu G, Ninomiya-T suji J et al. Role of the TAB2-related protein TAB3 in IL-1 and TNF signaling. EMBO J 2003; 22:6277–88.
Kanayama A, Seth RB, Sun L et al. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell 2004; 15:535–48.
Sato S, Sanjo H, Takeda K et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 2005; 6:1087–95.
Shim JH, Xiao C, Paschal AE et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 2005; 19:2668–81.
Wan YY, Chi H, Xie M et al. The kinase TAK1 integrates antigen and cytokine receptor signaling for T-cell development, survival and function. Nat Immunol 2006; 7:851–8.
Wang C, Deng L, Hong M et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001; 412:346–51.
Xia ZP, Sun L, Chen X et al. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 2009; 461:114–9.
Li X, Qin J. Modulation of Toll-interleukin 1 receptor mediated signaling. J Mol Med 2005; 83:258–66.
Xu M, Skaug B, Zeng W et al. A Ubiquitin replacement strategy in human cells reveals distinct mechanisms of IKK activation by TNFalpha and IL-1beta. Mol Cell 2009; 36:302–14.
Deng L, Wang C, Spencer E et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000; 103:351–61.
Lomaga MA, Yeh WC, Sarosi I et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40 and LPS signaling. Genes Dev 1999; 13:1015–24.
Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004; 16:3–9.
Park YC, Burkitt V, Villa AR et al. Structural basis for self-association and receptor recognition of human TRAF2. Nature 1999; 398:533–8.
Yin Q, Lin SC, Lamothe B et al. E2 interaction and dimerization in the crystal structure of TRAF6. Nat Struct Mol Biol 2009; 16:658–66.
Conze DB, Wu CJ, Thomas JA et al. Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor-and toll-like receptor-mediated NF-kappaB activation. Mol Cell Biol 2008; 28:3538–47.
Windheim M, Stafford M, Peggie M et al. Interleukin-1 (IL-1) induces the Lys63-linked polyubiquitination of IL-1 receptor-associated kinase 1 to facilitate NEMO binding and the activation of IkappaBalpha kinase. Mol Cell Biol 2008; 28:1783–91.
Yamamoto M, Okamoto T, Takeda K et al. Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling. Nat Immunol 2006; 7:962–70.
Bidere N, Snow AL, Sakai K et al. Caspase-8 regulation by direct interaction with TRAF6 in T-cell receptor-induced NF-kappaB activation. Curr Biol 2006; 16:1666–71.
Oeckinghaus A, Wegener E, Welteke V et al. Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation. EMBO J 2007; 26:4634–45.
Sun L, Deng L, Ea CK et al. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T-lymphocytes. Mol Cell 2004; 14:289–301.
Yamamoto M, Sato S, Saitoh T et al. Cutting Edge: Pivotal function of Ubc13 in thymocyte TCR signaling. J Immunol 2006; 177:7520–4.
King CG, Kobayashi T, Cejas PJ et al. TRAF6 is a T-cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med 2006; 12:1088–92.
Wu CJ, Ashwell JD. NEMO recognition of ubiquitinated Bcl10 is required for T-cell receptor-mediated NF-kappaB activation. Proc Natl Acad Sci USA 2008; 105:3023–8.
Hu S, Du MQ, Park SM, et al cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J Clin Invest 2006; 116:174–81.
Reiley WW, Jin W, Lee AJ et al. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T-cell responses. J Exp Med 2007; 204:1475–85.
Sorrentino A, Thakur N, Grimsby S et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol 2008; 10:1199–207.
Ea CK, Deng L, Xia ZP et al. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell 2006; 22:245–57.
Li H, Kobayashi M, Blonska M et al. Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappaB activation. J Biol Chem 2006; 281:13636–43.
Wu CJ, Conze DB, Li T et al. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation [corrected]. Nat Cell Biol 2006; 8:398–406.
Funakoshi-T ago M, Kamada N, Shimizu T et al. TRAF6 negatively regulates TNFalpha-induced NF-kappaB activation. Cytokine 2009; 45:72–9.
Tada K, Okazaki T, Sakon S et al. Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death. J Biol Chem 2001; 276:36530–4.
Yin Q, Lamothe B, Darnay BG et al. Structural Basis for the Lack of E2 Interaction in the RING Domain of TRAF2. Biochemistry 2009.
Mahoney DJ, Cheung HH, Mrad RL et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA 2008; 105:11778–83.
Varfolomeev E, Goncharov T, Fedorova AV, et al c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem 2008; 283:24295–9.
Bignell GR, Warren W, Seal S et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 2000; 25:160–5.
Brummelkamp TR, Nijman SM, Dirac AM et al. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003; 424:797–801.
Kovalenko A, Chable-Bessia C, Cantarella G et al. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003; 424:801–5.
Trompouki E, Hatzivassiliou E, Tsichritzis T et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003; 424:793–6.
Jin W, Chang M, Paul EM et al. Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J Clin Invest 2008; 118:1858–66.
Wright A, Reiley WW, Chang M et al. Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD. Dev Cell 2007; 13:705–16.
Yoshida H, Jono H, Kai H et al. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. J Biol Chem 2005; 280:41111–21.
Komander D, Lord CJ, Scheel H et al. The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol Cell 2008; 29:451–64.
Komander D, Reyes-Turcu F, Licchesi JD et al. Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep 2009; 10:466–73.
Jono H, Lim JH, Chen LF et al. NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway. J Biol Chem 2004; 279:36171–4.
Hutti JE, Shen RR, Abbott DW et al. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell 2009; 34:461–72.
Reiley W, Zhang M, Wu X et al. Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation. Mol Cell Biol 2005; 25:3886–95.
Massoumi R, Chmielarska K, Hennecke K et al. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006; 125:665–77.
Reiley WW, Zhang M, Jin W et al. Regulation of T-cell development by the deubiquitinating enzyme CYLD. Nat Immunol 2006; 7:411–7.
Boone DL, Turer EE, Lee EG et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004; 5:1052–60.
Lee EG, Boone DL, Chai S et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000; 289:2350–4.
Turer EE, Tavares RM, Mortier E et al. Homeostatic MyD88-dependent signals cause lethal inflamMation in the absence of A20. J Exp Med 2008; 205:451–64.
Wertz IE, O’Rourke KM, Zhou H et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004; 430:694–9.
Shembade N, Harhaj NS, Parvatiyar K et al. The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. Nat Immunol 2008; 9:254–62.
Shembade N, Parvatiyar K, Harhaj NS et al. The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-kappaB signalling. EMBO J 2009; 28:513–22.
Stilo R, Varricchio E, Liguoro D et al. A20 is a negative regulator of BCL10-and CARMA3-mediated activation of NF-kappaB. J Cell Sci 2008; 121:1165–71.
Komander D, Barford D. Structure of the A20 OTU domain and mechanistic insights into deubiquitination. Biochem J 2008; 409:77–85.
Lin SC, Chung JY, Lamothe B et al. Molecular basis for the unique deubiquitinating activity of the NF-kappaB inhibitor A20. J Mol Biol 2008; 376:526–40.
Werner SL, Kearns JD, Zadorozhnaya V et al. Encoding NF-kappaB temporal control in response to TNF: distinct roles for the negative regulators IkappaBalpha and A20. Genes Dev 2008; 22:2093–101.
Li L, Hailey DW, Soetandyo N et al. Localization of A20 to a lysosome-associated compartment and its role in NFkappaB signaling. Biochim Biophys Acta 2008; 1783:1140–9.
Hutti JE, Turk BE, Asara JM et al. IkappaB kinase beta phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-kappaB pathway. Mol Cell Biol 2007; 27:7451–61.
Coornaert B, Baens M, Heyninck K et al. T-cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol 2008; 9:263–71.
Duwel M, Welteke V, Oeckinghaus A et al. A20 negatively regulates T-cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J Immunol 2009; 182:7718–28.
Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009; 30:383–91.
Compagno M, Lim WK, Grunn A et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459:717–21.
Kato M, Sanada M, Kato I et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009; 459:712–6.
Ferch U, Kloo B, Gewies A et al. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2009; 206:2313–20.
Evans PC, Taylor ER, Coadwell J et al. Isolation and characterization of two novel A20-like proteins. Biochem J 2001; 357:617–23.
Enesa K, Zakkar M, Chaudhury H et al. NF-kappaB suppression by the deubiquitinating enzyme Cezanne: a novel negative feedback loop in pro-inflammatory signaling. J Biol Chem 2008; 283:7036–45.
Schweitzer K, Bozko PM, Dubiel W et al. CSN controls NF-kappaB by deubiquitinylation of IkappaBalpha. EMBO J 2007; 26:1532–41.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
Düwel, M., Hadian, K., Krappmann, D. (2010). Ubiquitin Conjugation and Deconjugation in NF-κB Signaling. In: Groettrup, M. (eds) Conjugation and Deconjugation of Ubiquitin Family Modifiers. Subcellular Biochemistry, vol 54. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-6676-6_7
Download citation
DOI: https://doi.org/10.1007/978-1-4419-6676-6_7
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-6675-9
Online ISBN: 978-1-4419-6676-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)